Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

Author： Poulakou Garyphallia   Giamarellou Helen  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.2, 2008-02, pp. : 225-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tigecycline for the treatment of infections due to resistant Gram-positive organisms

By Squires Ronald A   Postier Russell G  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 155-162

Informa Healthcare

Access to resources Recommend Favorite

Daptomycin: a novel agent for Gram-positive infections

By Tally F.P.   Zeckel M.   Wasilewski M.M.   Carini C.   Berman C.L.   Drusano G.L.   Oleson F.B.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 8, 1999-08 ,pp. : 1223-1238

Informa Healthcare

Access to resources Recommend Favorite

Newer developments in the treatment of Gram-positive infections

By Koomanachai Pornpan   Crandon Jared L   Nicolau David P  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 17, 2009-12 ,pp. : 2829-2843

Informa Healthcare

Access to resources Recommend Favorite

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

By Eisenstein Barry I  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 9, 2004-09 ,pp. : 1159-1169

Informa Healthcare

Access to resources Recommend Favorite

Novel agents for the treatment of resistant Gram-positive infections

By Woodford Neil  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 117-137

Informa Healthcare

Access to resources Recommend Favorite